October 28, 2013
ACTIVE BIOTECH Patent Opposition Rebuked 

Jenomic Rebuttal of Active Biotech Opposition
Jenomic Rebuttal of Active Biotech Oppos[...]
Adobe Acrobat document [2.6 MB]

June 2013 - January 2014
Jenomic’s Third  Party Observations of  ACTIVE BIOTECH  patent
application EP1406657 covering ANYARA

Full proceedings may be followed at:

https://register.epo.org/application?number=EP02746240&lng=en&tab=doclist

June 2013 - November 2013
Jenomic’s Third Party Observations of ACTIVE BIOTECH patent application EP1786449  covering ANYARA

Full proceedings may be followed at:

https://register.epo.org/application?number=EP05777870&lng=en&tab=doclist

About Jenomic Research Institute

 

Jenomic is a biotech company devoted to developing novel drugs and drug vehicles for treatment of cancer. These efforts are supported by a raft of peer- reviewed publications and worldwide patents/patent applications.

 

The research team is led by David S. Terman, MD, an emeritus member of the American Society of Clinical Investigation (academia's physician-scientist honor society), former Professor  of Medicine, Microbiology and Immunology and Founding Director of Cancer Biology Program at Baylor College of Medicine. He is currently Adjunct Professor of Biochemistry and Molecular Biology at UAB in Birmingham. Dr. Terman is cited in Who's Who in America 2008-2013

As seen in the Monterey Herald

Cancer researcher David S. Terman stands among piles of research and patent paperwork in his home office in Pebble Beach on Friday. Terman runs the Jenomic Research Institute in Carmel. (DAVID ROYAL/The Herald)